The DOI matches its Crossref record.
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
Abstract
BACKGROUND: Quantification of disease severity supports the development of evidence-based treatments. Assessments to capture clinical improvement in hidradenitis suppurativa (HS) can be improved. OBJECTIVES: This study aimed to validate the Hidradenitis Suppurativa Clinical Response (HiSCR), which is defined as a ≥ 50% reduction in inflammatory lesion count (sum of abscesses and inflammatory nodules, AN), and no increase in abscesses or draining fistulas in HS when compared with baseline as a meaningful clinical endpoint for HS treatment. METHODS: Patients with ≥ 3 ANs at baseline in a Phase II adalimumab trial for HS were included for analysis. HiSCR achievers vs. nonachievers were assessed at week 16 and week 52. Criteria measures included physician-rated assessments [Hurley stage, modified Sartorius score (MSS), and HS Physician's Global Assessment] and patient-reported outcomes (PROs: visual analogue pain scale, Dermatology Life Quality Index, and Work Productivity and Activity Impairment questionnaire). Test-retest reliability, convergent validity, responsiveness and predictive validity of HiSCR, and its meaningfulness to patients were assessed. RESULTS: Among 138 eligible study participants, the majority were female (69·6%) with a mean age of 36·7 years. The mean (median) MSS was 125·2 (85·5) at baseline. Test-retest reliability of the AN count was 0·91. HiSCR was significantly correlated with improvements in all physician-rated and PRO measures (Spearman's rho between -0·61 and -0·27, all P < 0·001). Improvements of all PROs in HiSCR achievers exceeded the respective meaningful improvement thresholds. CONCLUSIONS: In patients with HS with ≥ 3 ANs, HiSCR achievers had significant improvements in physician-rated and patient-reported HS disease severity and impact. HiSCR is a valid and meaningful endpoint for assessing HS treatment effectiveness in controlling inflammatory manifestations in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 807
Self-citationZouboulis, C. C., Tzellos, T., Kyrgidis, A., Jemec, G. B. E., Bechara, F. G., Giamarellos‐Bourboulis, E. J., Ingram, J. R., Kanni, T., Karagiannidis, I., Martorell, A., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15748 · Cited by 493
Self-citationGoldburg, S. R., Strober, B. E., & Payette, M. J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.090 · Cited by 486
Nguyen, T. V., Damiani, G., Orenstein, L. A. V., Hamzavi, I., & Jemec, G. B. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16677 · Cited by 391
Self-citationZouboulis, C. C., del Marmol, V., Mrowietz, U., Prens, E. P., Tzellos, T., & Jemec, G. B. E. (2015) · Dermatology · doi:10.1159/000431175 · Cited by 376
Self-citationKimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00022-3 · Cited by 343
Self-citationSafety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial
Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., Dinarello, C. A., van der Meer, J. W. M., Rigopoulos, D., & Giamarellos-Bourboulis, E. J. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3903 · Cited by 266
Zouboulis, C. C., Bechara, F. G., Dickinson‐Blok, J. L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A. B., Kirby, B., Martorell, A., Podda, M., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15233 · Cited by 259
Self-citationHidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis
González-Manso, A., Agut-Busquet, E., Romaní, J., Vilarrasa, E., Bittencourt, F., Mensa, A., Cantó, E., Aróstegui, J. I., & Vidal, S. (2021) · Dermatology · doi:10.1159/000511045 · Cited by 45
Metadata
- Authors
- Kimball, A. B., Jemec, G. B. E., Yang, M., Kageleiry, A., Signorovitch, J. E., Okun, M. M., Gu, Y., Wang, K., Mulani, P., & Sundaram, M.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-11
- Volume
- 171
- Issue
- 6
- Pages
- 1434-1442
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2149371387
- Cited by
- 214
- References
- 0
- FWCI
- 17.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.